These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25858158)

  • 1. Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects.
    Wood PL; Barnette BL; Kaye JA; Quinn JF; Woltjer RL
    Acta Neuropsychiatr; 2015 Oct; 27(5):270-8. PubMed ID: 25858158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease.
    Wood PL; Medicherla S; Sheikh N; Terry B; Phillipps A; Kaye JA; Quinn JF; Woltjer RL
    J Alzheimers Dis; 2015; 48(2):537-46. PubMed ID: 26402017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
    Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
    Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
    Kling MA; Goodenowe DB; Senanayake V; MahmoudianDehkordi S; Arnold M; Massaro TJ; Baillie R; Han X; Leung YY; Saykin AJ; Nho K; Kueider-Paisley A; Tenenbaum JD; Wang LS; Shaw LM; Trojanowski JQ; Kaddurah-Daouk RF;
    Alzheimers Dement; 2020 Sep; 16(9):1234-1247. PubMed ID: 32715599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease.
    Han P; Caselli RJ; Baxter L; Serrano G; Yin J; Beach TG; Reiman EM; Shi J
    JAMA Neurol; 2015 Mar; 72(3):333-9. PubMed ID: 25599520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics based identification of differential plasma proteins and changes in white matter integrity as markers in early detection of mild cognitive impaired subjects at high risk of Alzheimer's disease.
    Kumar A; Singh S; Verma A; Mishra VN
    Neurosci Lett; 2018 May; 676():71-77. PubMed ID: 29649488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease.
    Wood PL; Tippireddy S; Feriante J; Woltjer RL
    PLoS One; 2018; 13(3):e0191815. PubMed ID: 29513680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphometric network differences in ageing versus Alzheimer's disease dementia.
    Pichet Binette A; Gonneaud J; Vogel JW; La Joie R; Rosa-Neto P; Collins DL; Poirier J; Breitner JCS; Villeneuve S; Vachon-Presseau E; ;
    Brain; 2020 Feb; 143(2):635-649. PubMed ID: 32040564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of automated brain segmentation using a brain phantom and patients with early Alzheimer's dementia or mild cognitive impairment.
    Fellhauer I; Zöllner FG; Schröder J; Degen C; Kong L; Essig M; Thomann PA; Schad LR
    Psychiatry Res; 2015 Sep; 233(3):299-305. PubMed ID: 26211622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration.
    Kantarci K; Schwarz CG; Reid RI; Przybelski SA; Lesnick TG; Zuk SM; Senjem ML; Gunter JL; Lowe V; Machulda MM; Knopman DS; Petersen RC; Jack CR
    JAMA Neurol; 2014 Dec; 71(12):1547-54. PubMed ID: 25347157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity.
    Amlien IK; Fjell AM; Walhovd KB; Selnes P; Stenset V; Grambaite R; Bjørnerud A; Due-Tønnessen P; Skinningsrud A; Gjerstad L; Reinvang I; Fladby T
    Radiology; 2013 Jan; 266(1):295-303. PubMed ID: 23151827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.
    Lueg G; Gross CC; Lohmann H; Johnen A; Kemmling A; Deppe M; Groger J; Minnerup J; Wiendl H; Meuth SG; Duning T
    Neurobiol Aging; 2015 Jan; 36(1):81-9. PubMed ID: 25277040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroanatomical correlates of awareness of illness in patients with amnestic mild cognitive impairment who will or will not convert to Alzheimer's disease.
    Spalletta G; Piras F; Piras F; Sancesario G; Iorio M; Fratangeli C; Cacciari C; Caltagirone C; Orfei MD
    Cortex; 2014 Dec; 61():183-95. PubMed ID: 25481475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD).
    Wood PL; Locke VA; Herling P; Passaro A; Vigna GB; Volpato S; Valacchi G; Cervellati C; Zuliani G
    BBA Clin; 2016 Jun; 5():25-8. PubMed ID: 27051586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment.
    Auning E; Selnes P; Grambaite R; Šaltytė Benth J; Haram A; Løvli Stav A; Bjørnerud A; Hessen E; Hol PK; Muftuler løndalen A; Fladby T; Aarsland D
    Acta Psychiatr Scand; 2015 Feb; 131(2):139-47. PubMed ID: 25346330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.